Skip to main content

Table 1 Patient characteristics and clinical outcomes to axitinib

From: Response to post-axitinib treatment in patients with metastatic renal cell carcinoma

Characteristic N (%)
Gender  
 Male 18 (72 %)
 Female 7 (28 %)
Age at Start of Axitinib (years)a  
 Median (range) 59 (44-78)
Histology  
 Clear cell 24 (96 %)
 Unclassified 1 (4 %)
Prior Nephrectomy  
 No 2 (8 %)
 Yes 23 (92 %)
Prior Systemic Treatment  
 No 7 (28 %)
 Yes 18 (72 %)
 IFN and/or IL-2 11 (44 %)
 Sorafenib 9 (36 %)
 Sunitinib 6 (24 %)
 Temsirolimus 1 (4 %)
 Bevacizumab 1 (3 %)
 Otherb 4 (16 %)
Interval from Dx of Mets to Axitiniba  
 Median in months (range) 20.1 (0.2–49.9)
ECOG PS  
 0 7 (28 %)
 1 18 (72 %)
Heng Risk Groupc  
 Favorable 7 (30 %)
 Intermediate 15 (65 %)
 Unfavorable 1 (4 %)
Sites of Metastatic Disease  
 Lung 20 (80 %)
 Lymph nodes 13 (52 %)
 Bone 6 (24 %)
 Liver 5 (20 %)
 Adrenal 5 (20 %)
 Pancreas 4 (16 %)
 Brain 2 (8 %)
 Otherd 12 (48 %)
Best Response to axitinib  
 CR 1 (4 %)
 PR 13 (52 %)
 SD 10 (40 %)
 PD 1 (4 %)
Reason Axitinib Stopped  
 PD 21 (84 %)
 Toxicity 4 (16 %)
Duration of Treatment  
 Median in months (range) 11.2 (1.1–90.0)
  1. amissing for one patient
  2. balone or in combination: thalidomide (n = 3); gemcitabine,5-FU, ABX-EGF, capecitabine, lenalidomide, suramin, vinblastine (n = 1 each)
  3. cmissing for two patients
  4. dkidney/renal bed (n = 5); pleura (n = 4); abdominal wall, muscle, omentum, pelvic mass, retroperitoneum, soft tissue (n = 1 each)